In Vivo Protamine Titration Using Activated Coagulation Time to Neutralize Heparin Anticoagulation in Cardiac Surgery: Proof of Concept.

OBJECTIVE In vivo protamine titration (IVPT) is based on the observation of a plateau on the decay curve of the celite activated clotting times (ACTs) during protamine infusion for heparin reversal. The aim of the present study was to determine the optimal protamine/heparin ratio to reverse anticoagulation using IVPT curves. DESIGN Prospective, randomized study. SETTING Tertiary care university hospital. PARTICIPANTS The study comprised 138 patients undergoing elective cardiac surgery requiring cardiopulmonary bypass. INTERVENTIONS The control group was given a protamine infusion of 1.3 mg per 1 mg (100 U) of heparin over 21 minutes. ACT was measured every 3 minutes. In the test group, the protamine dose was prepared using the same ratio as for the control group, and ACT values were measured every 3 minutes until a plateau was reached (2 consecutive ACT values <160 s), at which time the protamine infusion was stopped. The protamine/heparin ratio, blood losses, transfusions, and heparin concentrations were recorded. RESULTS The protamine dose was lower in the test group (456.00 ± 105.66 mg [control group] v 295.25 ± 100.60 mg [test group]; p < 0.0001). The mean protamine/heparin ratios were 1.30 ± 0.10 (control group) and 0.81 ± 0.22 (test group) (p < 0.0001). Heparin concentrations were greater in the test group 15 minutes (0.10 [0-0.2] U/mL v 0 [0-0.1] U/mL; p = < 0.0001) and 3 hours (0 [0-0.1] U/mL v 0 [0-0] U/mL; p = 0.0002) after protamine infusion. There was no difference in the blood losses and transfusion requirements. CONCLUSIONS IVPT is safe and efficient in this low-risk population.

[1]  T. Gudbjartsson,et al.  2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. , 2019, British journal of anaesthesia.

[2]  C. Boer,et al.  A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. , 2016, Journal of cardiothoracic and vascular anesthesia.

[3]  M. Ozaki,et al.  Reappearance of circulating heparin in whole blood heparin concentration-based management does not correlate with postoperative bleeding after cardiac surgery. , 2014, Journal of cardiothoracic and vascular anesthesia.

[4]  P. Wouters,et al.  Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. , 2013, European journal of anaesthesiology.

[5]  Howard K. Song,et al.  2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. , 2011, The Annals of thoracic surgery.

[6]  J. Hirsh,et al.  Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? , 2004, The Journal of thoracic and cardiovascular surgery.

[7]  G. Gravlee,et al.  Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. , 1999, Anesthesiology.

[8]  D. Reich,et al.  Heparin and protamine titration do not improve haemostasis in cardiac surgical patients , 1998, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[9]  D. Jobes,et al.  Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. , 1995, The Journal of thoracic and cardiovascular surgery.

[10]  E. Spitznagel,et al.  Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. , 1994, The Journal of thoracic and cardiovascular surgery.

[11]  G. Delaria,et al.  Heparin-protamine mismatch. A controllable factor in bleeding after open heart surgery. , 1994, Archives of surgery.

[12]  J. Keeler,et al.  Protamine—the need to determine the dose , 1991, Anaesthesia.

[13]  E. Blackstone,et al.  Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. , 1986, The Annals of thoracic surgery.

[14]  A. Schwartz,et al.  Monitoring heparin anticoagulation and its neutralization. , 1981, The Annals of thoracic surgery.

[15]  F. Spencer,et al.  Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. , 1981, Annals of surgery.

[16]  M. Lie,et al.  Assay of heparin in plasma using a chromogenic substrate for activated factor X. , 1976, Thrombosis research.

[17]  J. W. Bland,et al.  Successful Use of a Reduced Dose of Protamine After Cardiopulmonary Bypass , 1976, Anesthesia and analgesia.

[18]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. , 1975, The Journal of thoracic and cardiovascular surgery.

[19]  T. Ryan,et al.  Reduced Protamine Dosage for Heparin Neutralization in Open‐Heart Operations , 1968, Circulation.